Bristol Myers Squibb is projected to report Q4 2025 revenue of approximately 11.75 billion and adjusted EPS of $1.52, driven largely by continued uptake of its oncology franchise led by Opdivo. Analysts note a 2.8 percent year-over-year top-line increase in the prior quarter, with a return on equity of 76.5 percent and net margin of 12.6 percent. Pipeline catalysts include late-stage readouts for a next-generation immunotherapy expected in mid-2026 and potential label expansions in hematology.

During Q3, Capital Management Corp VA boosted its position by 9.6 percent to 111,670 shares, valued at just over $5 million, while Norges Bank initiated a $1.55 billion stake in Q2. Charles Schwab Investment Management added 16.8 percent for a total of 70.8 million shares, and Arrowstreet Capital lifted its holding by 428.5 percent to 11.3 million shares. Market consensus across 20 analyst reports remains a Hold rating, with upside potential cited for immuno-oncology growth offset by pressure on legacy small-molecule franchises.

Bristol Myers Squibb declared a quarterly dividend of $0.63 per share, representing an annualized payout of $2.52 and a yield near 4.6 percent. The dividend payout ratio stands at 85.1 percent, reflecting a commitment to shareholder returns despite a debt-to-equity ratio of 2.39. Liquidity metrics remain solid, with a current ratio of 1.27 and quick ratio of 1.17, underscoring capacity to fund both R&D investments and dividends.